FindTrial
Sign In

A Study to Assess the Effectiveness of Posaconazole 300 mg in Patients with Weak Immune Systems

Evaluating effectiveness of 300 mg of Posaconazole in Immunocompromised patients: an observational study. - POSA-TDM-01

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/02/081462
Enrollment
25
Registered
2025-02-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control Intervention1: NIL: NIL

Sponsors

Bajaj Healthcare Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients prescribed posaconazole 300 mg tablet and are required to undergo TDM for fungal prophylaxis or treatment in various clinical settings.

Exclusion criteria

Exclusion criteria: Patients with contraindications to posaconazole use. Patients with incomplete medical records that impede thorough analysis. Non-compliant patients who fail to adhere to the prescribed treatment regimen or timing. Patients prescribed posaconazole for off-label indications not approved by regulatory authorities.

Design outcomes

Primary

MeasureTime frame
To determine the plasma concentrations of Posaconazole 300 mg using therapeutic drug monitoringTimepoint: Day 1 and Day 7—

Secondary

MeasureTime frame
To evaluate clinical outcomes, assess safety and adverse events, and analyze the correlation between TDM parameters and laboratory markersTimepoint: Day 1 and Day 7—

Countries

India

Contacts

Public ContactDr Dhananjay Lad

CROM Clinical Research & Medical Tourism Pvt. Ltd.

clinicalresearchgoa@gmail.com9158592177

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026